CyberKnife Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Tumor, Cancer, Vascular malformation, Others), By End-use (Hospitals, Outpatient facilities, Research and Manufacturing), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 638.55 Million
CAGR (2026-2031)	17.98%
Fastest Growing Segment	Cancer
Largest Market	North America
Market Size (2031)	USD 1722.05 Million

Market Overview

The Global CyberKnife Market will grow from USD 638.55 Million in 2025 to USD 1722.05 Million by 2031 at a 17.98% CAGR. The CyberKnife System is a robotic stereotactic radiosurgery platform designed to deliver high-energy radiation to tumors with sub-millimeter precision, serving as a non-invasive alternative to traditional surgery. The market is primarily driven by the escalating global burden of cancer and an aging population, which collectively necessitate efficient, patient-friendly outpatient treatment options. According to the American Cancer Society, in 2024, the projected number of new cancer diagnoses in the United States exceeded 2 million for the first time, underscoring the critical and growing demand for advanced oncological interventions.

However, widespread market expansion is significantly impeded by complex reimbursement frameworks and stringent prior authorization requirements that create administrative burdens for healthcare providers. These financial and regulatory hurdles often result in treatment delays or denials, limiting patient access to this technology and discouraging smaller medical facilities from investing in the high capital equipment required for such specialized radiosurgery.

Key Market Drivers

The rising global prevalence of cancer and neoplastic diseases serves as the primary catalyst propelling the Global CyberKnife Market, necessitating high-throughput and precise treatment modalities. As incidence rates climb due to aging demographics and environmental factors, healthcare systems are prioritizing advanced radiosurgery platforms that can deliver potent doses with sub-millimeter accuracy. This escalation in disease burden directly correlates with the need for non-invasive options to manage complex cases efficiently. According to the World Health Organization, February 2024, in the 'Global cancer burden growing' press release, over 35 million new cancer cases are predicted in 2050, representing a 77% increase from 2022 levels. This trajectory underscores the urgent requirement for scalable oncological solutions that can handle higher patient volumes without compromising clinical outcomes.

Concurrently, the market is expanding due to increasing patient demand for minimally invasive radiosurgery, which significantly reduces recovery times and hospital stays compared to traditional resection. Patients are actively seeking alternatives that offer superior tissue-sparing capabilities, driving hospitals to invest in robotic delivery systems to remain competitive and meet this preference. This shift in treatment choice is evidenced by substantial capital equipment investments in the sector. According to Accuray Incorporated, August 2024, in the 'Accuray Reports Fourth Quarter and Fiscal Year 2024 Financial Results', the company secured gross orders of $342.1 million for the fiscal year, reflecting a 10 percent increase driven by system placements. Furthermore, the financial scale of the leading manufacturer illustrates the sustained adoption of this technology; according to Accuray Incorporated, in 2024, full-year net revenue reached $446.6 million.

Download Free Sample Report

Key Market Challenges

Complex reimbursement frameworks and stringent prior authorization requirements constitute a substantial barrier to the expansion of the Global CyberKnife Market. These administrative hurdles impose a heavy operational burden on healthcare providers, often forcing them to divert clinical resources toward managing insurance approvals rather than delivering care. The unpredictability of payment models and the frequency of claim denials undermine the financial stability of offering specialized stereotactic radiosurgery. Consequently, medical facilities, particularly smaller centers with limited capital, are discouraged from investing in high-cost robotic platforms, as the return on investment becomes difficult to justify amidst such regulatory uncertainty.

This environment of delayed access directly suppresses procedure volumes and market utilization. According to the American Society for Radiation Oncology, in 2024, 92% of radiation oncologists reported that prior authorization requirements caused treatment delays for their patients, with nearly one-third of physicians indicating that these administrative barriers led to patients abandoning therapy entirely. When patients cannot access timely treatment due to bureaucratic inefficiencies, the demand for advanced interventions is artificially curtailed. This reduction in patient throughput hampers revenue generation for providers and signals a high-risk landscape for new adopters, effectively stalling the broader growth of the market.

Key Market Trends

The Global CyberKnife Market is witnessing a decisive Shift Towards Hypofractionated and Ultra-Hypofractionated Regimens, condensing therapy into fewer, high-precision sessions. Clinicians are increasingly leveraging the system’s sub-millimeter accuracy to deliver stereotactic body radiation therapy (SBRT) in one to five fractions, improving patient throughput and treatment adherence. This transition is supported by high-level clinical evidence validating the safety and efficacy of shortened schedules for indications like prostate cancer. According to Accuray Incorporated, October 2024, in the 'New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment' press release, the PACE-B trial demonstrated that patients treated with SBRT achieved a 95.8 percent five-year cancer control rate, a result comparable to conventional longer regimens but delivered in just five days.

Simultaneously, stakeholders are prioritizing Strategic Partnerships for Market Penetration in Emerging Economies, particularly in Asia-Pacific where healthcare modernization is accelerating. Manufacturers are establishing local joint ventures to navigate complex regulatory landscapes and meet the surging demand for advanced radiotherapy in countries like China. These localized strategies allow companies to bypass import barriers and price their systems competitively for regional hospitals. The success of this geographic diversification is evident in recent financial performances. According to Investing.com, August 2024, in the 'Earnings call: Accuray reports robust growth amid market challenges' article, Accuray reported that China revenue grew 27% year-over-year for fiscal 2024, underscoring the region's critical role in driving future market expansion.

Segmental Insights

The cancer application segment is currently experiencing the most rapid growth within the Global CyberKnife Market driven by the rising incidence of malignancies and the demand for non-invasive treatment alternatives. This expansion is supported by the system's ability to manage tumor motion accurately during procedures for indications including intracranial, lung, and prostate cancers. Additionally, ongoing approvals from regulatory bodies like the U.S. Food and Drug Administration continue to validate its efficacy for broader oncological uses. These factors collectively encourage healthcare institutions to adopt the technology, thereby securing the cancer segment's dominant developmental trajectory.

Regional Insights

North America currently leads the Global CyberKnife Market, driven primarily by the high adoption rate of robotic radiosurgery systems in the United States. This dominance is supported by the presence of key industry players, such as Accuray Incorporated, which facilitates easier access to technology and maintenance. Additionally, supportive reimbursement policies from the Centers for Medicare & Medicaid Services encourage healthcare providers to invest in these treatments. Continuous product clearances by the U.S. Food and Drug Administration further validate the technology, ensuring sustained demand across the region's established healthcare sector.

Recent Developments

• In October 2025, Accuray Incorporated announced a collaboration with 5D Clinics and Icon Group to treat the first patients in Melbourne, Australia, using the newest version of its robotic radiotherapy system. This initiative marked the expansion of the joint venture's network, aiming to improve access to stereotactic body radiation therapy across the country. The system's deployment allowed for more efficient delivery of radiation, minimizing treatment times and increasing daily patient capacity. The General Manager of 5D Clinics Australia highlighted that this partnership would significantly enhance cancer care options for local patients by bringing advanced technology closer to home.
• In January 2025, Accuray Incorporated received approval from China’s National Medical Products Administration for its latest generation robotic radiotherapy system and a new imaging synchronization technology. This regulatory clearance allowed the company to introduce its advanced precision treatment solutions, including real-time adaptive delivery, to the Chinese market. The President and CEO of Accuray noted that these approvals would enable medical teams in China to address the growing need for radiotherapy and improve patient access to high-precision cancer care. The launch aimed to bridge the significant gap between patient demand and treatment capacity in the region.
• In December 2024, Accuray Incorporated announced results from an international multicenter study demonstrating the effectiveness of its robotic radiotherapy system in treating brainstem metastases. The research, published in a leading cancer journal, analyzed outcomes for patients treated with stereotactic radiosurgery and fractionated stereotactic radiotherapy. The study revealed high local control rates at one, two, and three years post-treatment, with a low incidence of side effects. The Chief Medical Officer of Accuray stated that these results underscored the system's ability to safely deliver precise radiation to this delicate and critical region of the brain.
• In March 2024, Accuray Incorporated presented new clinical data at the Radiosurgery Society Meeting regarding the efficacy of its robotic radiotherapy system for prostate cancer. The findings indicated that the system could effectively treat high-risk and recurrent prostate cancer in significantly fewer sessions compared to conventional therapy. The data, derived from multiple studies, highlighted that patients achieved favorable biochemical control and maintained near-baseline urinary and bowel function three years post-treatment. The company emphasized that its real-time motion tracking technology was crucial for maintaining precision during these procedures, thereby preserving the patient's quality of life.

Key Market Players

• Accuray Incorporated
• Varian Medical Systems Inc.
• Koninklijke Philips N.V.
• Hitachi, Ltd.
• Mevion Medical Systems
• Mitsubishi Heavy Industries, Ltd.
• RaySearch Laboratories
• Siemens Healthineers AG
• ViewRay, Inc.

By Application	By End-use	By Region
Tumor Cancer Vascular malformation Others	Hospitals Outpatient facilities Research and Manufacturing	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global CyberKnife Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• CyberKnife Market, By Application:

• Tumor
• Cancer
• Vascular malformation
• Others

• CyberKnife Market, By End-use:

• Hospitals
• Outpatient facilities
• Research and Manufacturing

• CyberKnife Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE